정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 485 | Active, not recruiting | Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19 | Chronic Stable Illness | Drug: REGN10933+REGN10987 Drug: Placebo |
Phase 1 | Regeneron Pharmaceuticals | INDUSTRY | 974 | All | 18 Years ~ 90 Years | Regeneron Study Site, Tempe, Arizona, United States Regeneron Study Site, Rogers, Arkansas, United States Regeneron Study Site, Sacramento, California, United States Regeneron Study Site, Miami, Florida, United States Regeneron Study Site, Lincoln, Nebraska, United States Regeneron Study Site, Dayton, Ohio, United States Regeneron Study Site, Austin, Texas, United States |
| 484 | Not yet recruiting | Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19 | Corona Virus Infection | Diagnostic Test: Biochemistry blood test Diagnostic Test: Hematology blood test Diagnostic Test: D-Dimer test (coagulation) Diagnostic Test: Inflammatory markers Diagnostic Test: Vital signs Diagnostic Test: VAS scale Diagnostic Test: WHO Ordinal Score Diagnostic Test: COVID-19-Related Symptoms assessment Diagnostic Test: COVID-19-Impact on Quality-of-Life Questionnaire Diagnostic Test: POST- COVID-19 Functional Status Scale: Diagnostic Test: Pregnancy test Diagnostic Test: Physical examination Diagnostic Test: PK parameters Diagnostic Test: SARS-CoV-2 test (PCR) Diagnostic Test: ECG Drug: Treatment administration (twice a day) |
Phase 2 | MGC Pharmaceuticals d.o.o | INDUSTRY | 240 | All | 18 Years | Nazareth Hospital EMMS, Nazareth, North, Israel Rambam Medical Center, Haifa, Israel |
| 483 | Not yet recruiting | Study Evaluating Safety and Tolerability of Allocetra-OTS in Patients With COVID-19 | Covid19 | Drug: Allocetra-OTS | Phase 1 | Enlivex Therapeutics Ltd. | INDUSTRY | 18 | All | 18 Years ~ 80 Years | |
| 482 | Recruiting | Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults | Diabetes Type 2 | Biological: Biological samples | Phase 4 | Centre Hospitalier Regional d'Orleans | OTHER | 240 | All | 18 Years | CHR d'Orleans - Service Maladies Infectieuses, Orleans, France |
| 481 | Withdrawn | Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE) | Hematologic Malignancy | Drug: Hydroxychloroquine Sulfate 200 MG [Plaquenil] Drug: Azithromycin 250 MG Oral Capsule Drug: Placebo oral tablet Drug: Placebo oral capsule |
Phase 2 | Institut de cancerologie Strasbourg Europe | OTHER | 0 | All | 18 Years | Institut de Cancerologie Strasbourg Europe, Strasbourg, France |
| 480 | Completed | Study Evaluating the Safety and Efficacy of Autologous Non-Hematopoietic Peripheral Blood Stem Cells in COVID-19 | Coronavirus Disease 2019 (COVID-19) | Biological: Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC) Drug: COVID-19 standard care |
Phase 2 | Abu Dhabi Stem Cells Center | OTHER_GOV | 146 | All | 18 Years | Abu Dhabi Stem Cells Center, Abu Dhabi, United Arab Emirates |
| 479 | Completed | Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection | COVID-19 | Drug: Clazakizumab Other: Placebo |
Phase 2 | Columbia University, NYU Langone Health, CSL Behring | OTHER | 1 | All | 18 Years | Columbia University Medical Center / New York Presbyerian Hospital, New York, New York, United States |